Noteworthy Amortizing exploitable technology

The benefits of exploiting an enabling technology that can be sold more than once are apparent in Alkermes Inc.'s strategy in developing its ProLease peptide drug delivery technology.

ALKS acquired the technology in 1993 through its $30 million acquisition of privately held Enzytech Inc. Since the acquisition, ALKS is attempting to recoup the investment by partnering with a number of companies to develop the technology for a range of indications.